RxDoctor Payments Data

Bryan Wasson, DO

Internal Medicine · Flower Mound, TXNPI 1972537801

Payments from drug & device makers

$136,196in general payments, 2019–2025

Across 1,113 payments — averaging $122.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$100K
  • Amarin Pharma, Inc.$12K
  • Esperion Therapeutics, Inc.$7K
  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • AbbVie$2K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$6400%
  • Speaking & faculty fees$103,14076%
  • Travel & lodging$9,1767%
  • Food & beverage$23,18917%
  • Education$510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)206$100,049
Amarin Pharma, Inc.39$12,378
Esperion Therapeutics, Inc.36$6,557
AstraZeneca72$2,030
Boehringer Ingelheim76$1,983
AbbVie(2 entities)125$1,763
Novo Nordisk105$1,660
Lilly USA, LLC73$1,272
Pfizer54$1,035
Bayer39$851
GSK45$778
Radius Health, Inc.16$508
Dexcom, Inc.5$422
Novartis15$417
Takeda Pharmaceuticals U.S.A., Inc.36$293
Abbott9$290
Medtronic(3 entities)11$279
Merck22$276
Axsome Therapeutics, Inc.9$260
Insulet Corporation6$242
Biohaven Pharmaceutical Holding Company Ltd.11$202
Johnson & Johnson5$171
Stryker2$141
E.r. Squibb & Sons, L.L.C.3$138
Sanofi-aventis U.S. LLC6$137
Lexicon Pharmaceuticals, Inc.2$128
Phathom Pharmaceuticals, Inc.1$125
Regeneron1$123
Cvrx, Inc.1$112
IBSA Pharma Inc.5$108
Madrigal Pharmaceuticals4$101
Sanofi4$95
Shield Therapeutics Inc3$93
Biohaven Pharmaceuticals, Inc.2$85
Astellas Pharma US Inc5$82
Myocardial Solutions, Inc.1$69
Xeris Pharmaceuticals, Inc.3$63
Tolmar, Inc.3$61
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$57
Exact Sciences3$56
Jazz Pharmaceuticals Inc.3$56
Romark Laboratories, LC6$50
Genentech USA, Inc.3$47
Recordati_rare_diseases_inc.2$38
Adlon Therapeutics L.p.2$38
Arbor Pharmaceuticals, Inc.2$33
Endo Pharmaceuticals Inc.2$29
Currax Pharmaceuticals LLC2$29
Corcept Therapeutics1$25
Hologic Sales And Service, LLC1$25
Corium, LLC1$24
Almatica Pharma LLC1$23
Nalpropion Pharmaceuticals LLC2$23
Lundbeck LLC1$21
Ardelyx, Inc.1$20
Shire North American Group Inc1$19
Gilead1$18
Teva Pharmaceuticals USA, Inc.1$17
Acella Pharmaceuticals, LLC1$16
Intuity Medical Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$136,196 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$86,917
Medicare patients
174
Services billed
41,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin117$157,471
MounjaroTirzepatide87$121,521
OzempicSemaglutide59$66,466
Dupixent PenDupilumab14$59,811
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/733$24,789
Repatha SureclickEvolocumab32$22,428
VascepaIcosapent Ethyl21$20,441
EliquisApixaban13$19,137
FarxigaDapagliflozin Propanediol11$16,327
Repatha SyringeEvolocumab23$13,401
LinzessLinaclotide18$12,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,542
FiaspInsulin Aspart (Niacinamide)12$9,762
Breo ElliptaFluticasone/Vilanterol15$8,650
Icosapent Ethyl19$6,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,983$157,471117 claims
Lilly USA, LLCMounjaro$1,272$121,52187 claims
Novo NordiskOzempic, Fiasp$1,660$76,22871 claims
GSKTrelegy Ellipta, Breo Ellipta$778$20,19231 claims
PfizerEliquis$1,035$19,13713 claims
AstraZenecaFarxiga$2,030$16,32711 claims
AbbVieLinzess, Synthroid, Armour Thyroid$1,763$15,17664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Flower Mound

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →